Entrada Therapeutics (TRDA) Insider Trading & Ownership $17.60 +0.46 (+2.68%) (As of 11/1/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Entrada Therapeutics (NASDAQ:TRDA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.59%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$151,226.80Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$667,461.49 Get TRDA Insider Trade Alerts Want to know when executives and insiders are buying or selling Entrada Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TRDA Insider Buying and Selling by Quarter Ad Porter & CompanyBanking failure dead aheadIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Entrada Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/16/2024Natarajan SethuramanInsiderSell600$18.00$10,800.00 9/26/2024Nathan J DowdenCOOSell847$16.00$13,552.00 9/9/2024Kory James WentworthCFOSell3,195$14.97$47,829.15 9/9/2024Natarajan SethuramanInsiderSell2,642$15.09$39,867.78 9/9/2024Nathan J DowdenCOOSell1,904$15.07$28,693.28 9/6/2024Natarajan SethuramanInsiderSell600$15.24$9,144.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/6/2024Nathan J DowdenCOOSell399$15.19$6,060.81 7/15/2024Dipal DoshiCEOSell1,600$17.81$28,496.00 7/15/2024Natarajan SethuramanInsiderSell638$18.00$11,484.00 7/12/2024Dipal DoshiCEOSell300$18.00$5,400.00 7/12/2024Natarajan SethuramanInsiderSell600$18.00$10,800.00 7/8/2024Kory James WentworthCFOSell1,758$14.95$26,282.10 6/13/2024Dipal DoshiCEOSell1,000$16.17$16,170.00 5/20/2024Natarajan SethuramanInsiderSell9,675$15.19$146,963.25 5/16/2024Dipal DoshiCEOSell1,800$15.00$27,000.00 5/16/2024Natarajan SethuramanInsiderSell1,000$15.00$15,000.00 5/8/2024Peter S KimDirectorBuy2,276$14.04$31,955.04 4/8/2024Peter S KimDirectorBuy2,600$13.57$35,282.00 3/28/2024Peter S KimDirectorBuy1,512$13.75$20,790.00 3/25/2024Peter S KimDirectorBuy3,180$13.36$42,484.80 3/21/2024Peter S KimDirectorBuy704$13.24$9,320.96 3/19/2024Peter S KimDirectorBuy900$12.66$11,394.00 2/15/2024Dipal DoshiCEOSell1,000$15.00$15,000.00 1/16/2024Dipal DoshiCEOSell1,000$15.99$15,990.00 12/26/2023Kory James WentworthCFOSell94$16.67$1,566.98 12/22/2023Kory James WentworthCFOSell10,206$15.69$160,132.14 12/20/2023Dipal DoshiCEOSell1,000$15.00$15,000.00 11/13/2023Dipal DoshiCEOSell1,000$16.23$16,230.00 (Data available from 1/1/2013 forward) TRDA Insider Trading Activity - Frequently Asked Questions Who is on Entrada Therapeutics's Insider Roster? The list of insiders at Entrada Therapeutics includes Bros. Advisors Lp Baker, Dipal Doshi, John F Crowley, Kory James Wentworth, Natarajan Sethuraman, Nathan J Dowden, Nerissa Kreher, and Peter S Kim. Learn more on insiders at TRDA. What percentage of Entrada Therapeutics stock is owned by insiders? 7.59% of Entrada Therapeutics stock is owned by insiders. Learn more on TRDA's insider holdings. Which Entrada Therapeutics insiders have been buying company stock? The following insider purchased TRDA shares in the last 24 months: Peter S Kim ($151,226.80). How much insider buying is happening at Entrada Therapeutics? Insiders have purchased a total of 11,172 TRDA shares in the last 24 months for a total of $151,226.80 bought. Which Entrada Therapeutics insiders have been selling company stock? The following insiders have sold TRDA shares in the last 24 months: Dipal Doshi ($518,743.50), Kory James Wentworth ($723,997.87), Natarajan Sethuraman ($369,825.03), Nathan J Dowden ($365,434.77), and Nerissa Kreher ($266,748.00). How much insider selling is happening at Entrada Therapeutics? Insiders have sold a total of 143,702 Entrada Therapeutics shares in the last 24 months for a total of $2,244,749.17 sold. More Insider Trading Tools from MarketBeat Related Companies Catalyst Pharmaceuticals Insider Trades Arrowhead Pharmaceuticals Insider Trades CG Oncology Insider Trades Amphastar Pharmaceuticals Insider Trades ImmunityBio Insider Trades ACADIA Pharmaceuticals Insider Trades 23andMe Insider Trades Scholar Rock Insider Trades Longboard Pharmaceuticals Insider Trades IDEAYA Biosciences Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Big Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock2 Stocks to Buy and 1 to Sell - Smart Moves for Investors3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside This page (NASDAQ:TRDA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
